KOLs Discussing TRITON
TRITON Key Slides & Visuals
Slides shared by KOLs at ASCO 2026 (Rapid Oral Abs 8515, presented by @FSkoulidis). Click any image to expand.
Top Tweets on TRITON
Day 2 #ASCO26 highlights: Breast Cancer: 1. #KN522 (update): IO + Chemo TNBC 2. #OPTIMA: Adj Chemo HR+ 3. #lidERA: Adj SERD HR+ 4. #SENOMAC: ALND omission Prostate Ca 5. #TALAPRO3: PARPi NSCLC: 6. #TRITON: Dual ICI mNSCLC #OncTwitter @ASCO @OncoAlert 1/7 https://t
Alright. Abstracts are out. This is one of the studies I really wanted to see… and I’m disappointed. TRITON IA (T+D+CT vs P+CT, STK11/KEAP1/KRAS NSQ mNSCLC): only ORR + DoR reported, PFS still blinded. ORR within noise (39% vs 35%) but durability intriguing (100% vs 58% in https:
🆙 #ASCO26 #LCSM Rapid Oral 🔥TRITON: Tremelimumab + durvalumab + CT vs pembro + CT in 1L NSQ NSCLC with STK11, KEAP1, and/or KRAS mut ✅ORR 39% vs 34.9% ✅KRAS: ORR 48% vs 33.3% 🎙️ @FSkoulidis 🔢8515 ☑️NCT06008093 🔗 https://t.co/XCafTEYOfG @OncoAlert @Larvol @ASCO @KRASKickers https:
#ASCO26 #TRITON @FSkoulidis I’m struggling to understand the value of highlighting secondary endpoints while the primary endpoint remains blinded. The reported improvements in ORR and DoR for tremelimumab + durvalumab + chemotherapy versus pembrolizumab + chemotherapy are https:
Dr. @FSkoulidis presents randomized phase 2b TRITON study at #ASCO26: chemo + durvalumab + tremelimumab vs chemo + pembro in non-squamous NSCLC with STK11, KEAP1, and/or KRAS mutations. RR numerically favors dual checkpoint in the challenging STK11 and KRAS subsets. PFS pending.
🚨 #ASCO26 | TRITON interim analysis Tremelimumab + durvalumab + chemo vs pembrolizumab + chemo 1L NSQ mNSCLC with STK11/KEAP1/KRAS mutations #️⃣Abstr 8515 🧬 Phase 2b randomized US study T+D+CT n=41 vs P+CT n=43 IA focused on ORR, DoR, and safety 🎯 Response: ・cORR 39.0% vs https
🫁 #ASCO26 TRITON asks the uncomfortable question in 1L NSCLC: Can CTLA-4 rescue the “cold” STK11/KEAP1/KRAS-mutant subgroup? 👀 📌 Phase 2b, n=84 📌 1L non-squamous mNSCLC 📌 STK11 and/or KEAP1 and/or KRAS mutated ⚔️ T+D+chemo vs pembro+chemo 📊 Key signal: ✅ ORR: 39.0% vs https:/
✅ Some NSCLC subgroups continue to challenge our current immunotherapy strategies more than others. At #ASCO26, the TRITON study explores whether adding anti-CTLA-4 can improve outcomes in STK11-, KEAP1-, and KRAS-mutated nonsquamous mNSCLC — a population often associated ht
New data from the phase 2b TRITON study suggest that adding tremelimumab to durvalumab + chemotherapy may improve response outcomes in patients with STK11-, KEAP1-, and/or KRAS-mutated metastatic non-squamous NSCLC. Presented by Dr. Ferdinandos Skoulidis at #ASCO26, interim http
TRITON IA: in 1L NSQ mNSCLC with STK11/KEAP1/KRAS alterations, Tremelimumab+Durvalumab+CT showed generally numerically higher ORRs vs Pembro+CT. Eagerly awaiting further data including PFS/OS. #ASCO26 https://t.co/oi38QjJXnJ
TRITON study at #ASCO26: chemo + durva + treme vs chemo + pembro in non-squamous NSCLC w/ STK11, KEAP1, and/or KRAS mutations. ⬆️ORR w/ dual ICI, except KEAP1-mutant outcomes appear similar. Small pt #’s & overlapping co-mutations make these exploratory signals. PFS pendin
😳TIL you can present a Kaplan Meier curve @ASCO with confidence intervals wide as an ocean, number at risk < 20 in both groups, & primary endpoint unknown.
Overview
TRITON (NCT06008093) is a Phase 2b randomized U.S. trial testing whether dual checkpoint blockade with tremelimumab (anti-CTLA-4) + durvalumab (anti-PD-L1) + platinum chemotherapy outperforms pembrolizumab + chemotherapy as first-line treatment in non-squamous metastatic NSCLC patients carrying STK11, KEAP1, and/or KRAS mutations — a subgroup historically associated with poor response to single-agent anti-PD-1 therapy. The trial is led by Ferdinandos Skoulidis, MD PhD (MD Anderson). Interim analysis was presented as a Rapid Oral at #ASCO26 (Abstract 8515) on May 30, 2026; the primary endpoint of PFS remains blinded.
Study Design
Phase 2b randomized, open-label U.S. trial. 84 patients randomized at the November 2025 data cut-off (full target enrollment 100 per CT.gov). Primary endpoint PFS remains blinded at this interim analysis.
Population
Treatment-naïve metastatic non-squamous NSCLC with STK11, KEAP1, and/or KRAS mutations — a population historically resistant to anti-PD-1 monotherapy and chemo-IO combos.
Intervention
Experimental: Tremelimumab + Durvalumab + platinum-pemetrexed chemo. Control: Pembrolizumab + platinum-pemetrexed chemo.
Endpoints (per CT.gov)
Primary: PFS (randomized; 6-mo; 12-mo) — BLINDED at IA. Secondary: OS (12/24-mo; overall + mutation subset), ORR, DoR, TFST, AEs. Interim reported ORR, DoR, and Grade 3/4 AE rates.
Reported Interim Results
Objective Response Rate (Secondary)
Confirmed ORR was 39.0% with T+D+CT vs 34.9% with P+CT (95% CI 24.1–54.0 vs 20.6–49.1 — single-source OncUpdates) — confidence intervals overlap substantially in the overall population. In the prespecified KRAS-mutant subgroup, ORR was 48.0% vs 33.3%, numerically favoring the dual-checkpoint arm. STK11- and KEAP1-only subgroup ORRs were reported on the Skoulidis slide but are not in any indexed public recap and should be read from the slide deck above.
Overall ORR 39.0% vs 34.9% · KRAS subset 48.0% vs 33.3%Sources: OncoDaily TRITON oncolibrary · OncUpdates ASCO 2026 preview (Skoulidis Abs 8515) — both confirm overall ORR; KRAS subset confirmed by OncoDaily; CIs single-source OncUpdatesDuration of Response (Secondary)
Median DoR was not reached (NR) with T+D+CT vs 6.4 months with P+CT. At the 6-month landmark, 100% of responders in the T+D+CT arm remained in response vs 58.3% in the P+CT arm — the most differentiated efficacy signal in the interim readout. Both numbers are independently confirmed across two sources.
Median DoR NR vs 6.4 mo · 6-mo landmark 100% vs 58.3%Sources: OncoDaily TRITON oncolibrary · OncUpdates ASCO 2026 preview — dual-confirmedProgression-Free Survival (Primary — BLINDED)
The primary endpoint of PFS remains blinded to the sponsor at this interim analysis — the data are too immature to evaluate. Per ClinicalTrials.gov, the trial's primary endpoints are PFS in randomized participants, PFS at 6 months, and PFS at 12 months. As @GlopesMd noted: "ORR within noise (39% vs 35%) but durability." @Alfdoc2 flagged the limit of interpreting secondary endpoints while PFS is blinded.
PFS BLINDED at interim · primary endpoint per CT.govSources: OncoDaily · OncUpdates · ClinicalTrials.gov NCT06008093 — all confirm PFS is primary and blinded at IAOverall Survival (Secondary — Immature)
OS data are too immature to evaluate at this interim. OS at 12 and 24 months — both overall and in the STK11/KEAP1/KRAS mutation subset — are prespecified secondary endpoints per ClinicalTrials.gov. (Note: one secondary source — GeneOnline — incorrectly labels OS as the trial's primary endpoint; CT.gov, OncoDaily, OncUpdates, and the AstraZeneca ASCO 2026 schedule all confirm PFS is primary.)
OS Not reported at IA · immatureSources: ClinicalTrials.gov NCT06008093 · OncoDaily · OncUpdatesSafety & Tolerability
Grade 3/4 adverse events were broadly comparable between arms: 41.5% with T+D+CT vs 41.9% with P+CT (dual-confirmed). Additional safety detail (single-source OncoDaily): treatment-related AEs leading to discontinuation 2.4% vs 4.7%; treatment-related deaths 0% vs 2.3%. Specific immune-mediated AE rates are not in any indexed source and should be read from the Skoulidis slide deck above. KOL recaps from @SuyogCancer, @HHorinouchi, @M_Torasawa describe safety as "broadly comparable" between arms.
G3/4 AEs 41.5% vs 41.9% · TRAE d/c 2.4% vs 4.7% · TRAE deaths 0% vs 2.3%Sources: OncoDaily TRITON oncolibrary (TRAE discontinuation + deaths — single-source) · OncUpdates ASCO 2026 preview (G3/4 AEs — dual-confirmed)
